Registro Sanitario Fees 2026: COFEPRIS Registration Costs by Risk Class
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The official fees for Mexican medical device health registrations are charged under Article 195-A of the Federal Rights Law. For 2026 the three class amounts are: Class I 16,498.70 Mexican pesos, Class II 24,198.08 Mexican pesos, and Class III 30,797.57 Mexican pesos. Renewals and other registration amendments are charged at 75% of the corresponding registration fee; a change of registration holder name and other holder-related changes are charged at 50%. These percentages are not interchangeable, and they compound across the device lifecycle: every renewal and every amendment multiplies the class fee set at first registration, so a classification decision made once echoes through every later payment in the product’s history. A fee review at the start of the project is therefore a classification exercise as much as an arithmetic one.
- 2026 first-registration fees: Class I 16,498.70 pesos, Class II 24,198.08 pesos, Class III 30,797.57 pesos.
- Renewals and other registration amendments are charged at 75% of the corresponding registration fee.
- A change of holder name and other holder-related changes are charged at 50%.
- Import-permit-related fees fall under Article 195-G, with itemised amounts governed by the publication for the year in question.
- The proposed 2027 increases remain in the legislative process and are not in force; they should not be written into quotations or contracts.
2. Legal basis
Four provisions together determine what a registration costs in Mexico: the fee article that prices first registrations by risk class, the charging rules that set the percentage tiers for renewals and amendments, the article covering import-permit fees, and the regulation articles that make the risk class drive the fee tier. Each is set out below.
| Ley Federal de Derechos (LFD) | Article 195-A | Health registration official fees are charged by risk class |
| Ley Federal de Derechos (LFD) | Charging rules of Article 195-A | Other registration amendments and renewals at 75%; holder name changes and similar at 50% |
| Ley Federal de Derechos (LFD) | Article 195-G | Import-permit-related fees (itemised amounts per the publication for the year) |
| Reglamento de Insumos para la Salud (RIS), amendment decree DOF 2026-04-24 | Article 83 / Article 83 Bis | The class determines the fee tier |
3. Expert insights
2026 first-registration official fees (in Mexican pesos)
| Class I | 16,498.70 |
| Class II | 24,198.08 |
| Class III | 30,797.57 |
Insight one: official fees are adjusted annually. The Federal Rights Law is updated each year with the fiscal package, and the amounts in force are those published for the year. Multi-year projects should be costed against the fee schedule of the year of submission, not against the previous year’s figures. Carrying stale numbers into a budget is a small error at filing stage but a compounding one across a portfolio of registrations.
Insight two: renewals and amendments are charged proportionally, at two tiers. Renewals and other registration amendments are charged at 75% of the corresponding registration fee; a change of registration holder name and other holder-related changes are charged at 50%. The two tiers are different and must not be mixed in budgeting. Keeping the categories separate in the cost model makes it possible to price holder-related workstreams accurately, which matters when transfers or corporate reorganisations are on the table.
Insight three: a classification error propagates across the whole fee lifecycle. The class determines the tier for first registration and also the base for every subsequent renewal and amendment. The financial impact of a classification judgement is therefore long-lived. Getting the class right at the outset is one of the cheapest cost controls available in the entire Mexican process, since correcting it later means paying again on a different base.
Insight four: the 2027 increase is still in the legislative process. Media reporting indicates that the draft 2027 revision of the Federal Rights Law proposes increases of approximately 71% / 74% / 106% for the three registration classes, but as of the verification date the subsequent legislative steps remain outstanding. This is not a standard in force and should not be written into quotations or contracts. Treating it as a range for sensitivity analysis, rather than a committed number, keeps commercial documents honest.
Insight five: official fees are only part of the total cost. The larger cost items are usually dossier preparation, translation and notarisation or legalisation, the certificate of free sale, the holder arrangement, and the registration submission service itself; import permits carry separate fees. Budgets that track only the official fee therefore systematically understate the real cost of market entry, and the non-official items should be itemised explicitly so that management sees the full cost of entering and staying in the market.
4. Practical recommendations
- Structure the budget under four separate lines — first registration, renewal (75%), amendments (75% or 50%) and import permits — so that each cost driver is visible and none is buried inside a blended figure.
- Re-check the fee schedule once each year after the fiscal package is published, and cost multi-year projects at the amounts for the year of submission.
- Finalise the classification conclusion before costing, so the project does not have to be recalculated midway through a change of class.
- Treat the 2027 increases as proposed: carry a floating range in the budget rather than locking in a figure that is not yet law.
- List translation, notarisation and holder-service costs separately and do not fold them into the official-fee estimate.
5. Verification checklist
- □ The three class amounts have been costed on the 2026 fee schedule
- □ Renewals and amendments are budgeted separately at the 75% / 50% tiers
- □ The classification conclusion has been finalised
- □ The 2027 increases are treated as proposed and not in force
- □ Translation, notarisation and holder-service costs are listed separately
- □ Import permit fees are included as a separate line
Regulatory information verified as of October 28, 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us